TherapeuticsMD Announces Pricing Of Public Offering Of Common Stock

TherapeuticsMD, Inc. (OTCQB: TXMD) today announced the pricing of its previously announced underwritten public offering of 29,411,765 shares of its common stock, offered at a price of $1.70 per share to the public. The gross proceeds to TherapeuticsMD from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts, commissions, and other estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about March 20, 2013, subject to the satisfaction of customary closing conditions. TherapeuticsMD has granted the underwriters a 30-day option to purchase up to an aggregate of 4,411,765 additional shares of common stock to cover over-allotments, if any.

Jefferies LLC acted as sole book-running manager for the offering, and Noble Financial Capital Markets acted as co-manager.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and has been declared effective by the SEC. A preliminary prospectus supplement relating to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at When available, copies of the final prospectus supplement may also be obtained from the offices of Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone at (877) 547-6340, or by e-mail at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

If you liked this article you might like

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

TherapeuticsMD Rejected by FDA, Delay Could Be Fatal

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Penn National Gaming, Wynn Resorts: 'Mad Money' Lightning Round

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)